tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Lerut JP et al. Is minimal, [almost] steroid-free immunosuppression a safe approach in adult liver transplantation? Long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study. 2014 Ann. Surg. pmid:25379858
Colombani PM et al. Liver transplantation in infants younger than 1 year of age. 1996 Ann. Surg. pmid:8645039
Fealy MJ et al. Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival. 1994 Ann. Surg. pmid:7507657
Petruzzo P et al. Outcomes after bilateral hand allotransplantation: a risk/benefit ratio analysis. 2015 Ann. Surg. pmid:24646555
Jain A et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. 1999 Ann. Surg. pmid:10493490
Lerut J et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. 2008 Ann. Surg. pmid:19092340
Schneeberger S et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. 2013 Ann. Surg. pmid:23001085
Bartlett ST et al. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. 1996 Ann. Surg. pmid:8857849
Sho M et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. 2002 Ann. Surg. pmid:12409674
McCourtie AS et al. Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition. 2010 Ann. Thorac. Surg. pmid:20494024
Laubach VE Invited commentary. 2010 Ann. Thorac. Surg. pmid:20494025
Li S et al. Intrathymic inoculation of donor bone marrow induces long-term acceptance of lung allografts. 2003 Ann. Thorac. Surg. pmid:12537225
Sugita M et al. Pharmacologic modulation of alveolar liquid clearance in transplanted lungs by phentolamine and FK506. 2009 Ann. Thorac. Surg. pmid:19699927
Moffatt-Bruce S Invited commentary. 2009 Ann. Thorac. Surg. pmid:19699928
Thyagarajan GK et al. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. 1997 Ann. Thorac. Surg. pmid:9386723
Leshnower BG et al. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. 2008 Ann. Thorac. Surg. pmid:18805178
Chambers DJ Invited commentary. 2008 Ann. Thorac. Surg. pmid:18805179
Nathan M et al. Cyclosporin A but not FK-506 protects against dopamine-induced apoptosis in the stunned heart. 2005 Ann. Thorac. Surg. pmid:15854943
Hirai T et al. A short course of FK506 can induce limited donor-specific graft acceptance. 1994 Ann. Thorac. Surg. pmid:7520685
Armitage JM et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. 1992 Ann. Thorac. Surg. pmid:1379032
Oto T et al. Calcineurin inhibitor-related cholestasis complicating lung transplantation. 2010 Ann. Thorac. Surg. pmid:20417810
Groetzner J et al. Cardiac transplantation in pediatric patients: fifteen-year experience of a single center. 2005 Ann. Thorac. Surg. pmid:15620914
Inutsuka K et al. Reconstruction of trachea and carina with immediate or cryopreserved allografts in dogs. 1996 Ann. Thorac. Surg. pmid:8893587
Bolman RM Advantage--FK 506: reduced chronic rejection for lung transplant recipients. 1995 Ann. Thorac. Surg. pmid:7545888
Keenan RJ et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. 1995 Ann. Thorac. Surg. pmid:7545889
Foroncewicz B et al. A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. 2013 Ann. Transplant. pmid:23896824
Arreola-Guerra JM et al. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. 2016 Ann. Transplant. pmid:26879833
Girman P et al. The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. 2001 Ann. Transplant. pmid:11803619
Steinebrunner N et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. 2014 Ann. Transplant. pmid:24457606
Wu YJ et al. Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. 2016 Ann. Transplant. pmid:26782179
Aguiar D et al. Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. 2017 Ann. Transplant. pmid:28461684
Ueda K et al. Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry. 2014 Ann. Transplant. pmid:24535029
Augusto JF et al. Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. 2013 Ann. Transplant. pmid:23872516
Zegarska J et al. Mycophenolic Acid Metabolites Acyl-Glucuronide and Glucoside Affect the Occurrence of Infectious Complications and Bone Marrow Dysfunction in Liver Transplant Recipients. 2015 Ann. Transplant. pmid:26313036
Bułanowski M et al. Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. 2012 Jul-Sep Ann. Transplant. pmid:23018257
Baran DA and Galin ID "One size fits all": immunosuppression in cardiac transplantation. 2003 Ann. Transplant. pmid:12848376
Eguchi S et al. Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. 2007 Ann. Transplant. pmid:18344932
Garaix F et al. Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study. 2018 Ann. Transplant. pmid:30093607
Matia I et al. Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats. 2014 Ann. Transplant. pmid:24815872
Gardiner KM et al. Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. 2016 Ann. Transplant. pmid:26729299
Tang JT et al. A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. 2018 Ann. Transplant. pmid:29735966
Abdel Halim M et al. Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient. 2010 Jan-Mar Ann. Transplant. pmid:20305320
Bösmüller C et al. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. 2012 Ann. Transplant. pmid:23274323
Olczak-Kowalczyk D et al. The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. 2012 Ann. Transplant. pmid:23274327
Zakliczyński M et al. Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience. 2005 Ann. Transplant. pmid:16218032
Ruangkanchanasetr P et al. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients. 2016 Ann. Transplant. pmid:27980321
Malinowski M et al. The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study. 2009 Apr-Jun Ann. Transplant. pmid:19487793
Kishida N et al. Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. 2016 Ann. Transplant. pmid:27956735
Albano L et al. Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. 2016 Ann. Transplant. pmid:27122116
Wyzgał J et al. Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. 2007 Ann. Transplant. pmid:18173063